ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0970

Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
Abstract Number: 0971

Ligand-Receptor Analysis Reveals Myeloid-Mediated Pro-Inflammatory Responses and Loss of Mesenchymal Signaling Driven by TNFR1 in Experimental Pulmonary Hypertension
Abstract Number: 0972

Downregulated Fli1 in Scleroderma Myeloid Cells Contributes to Cardiac Fibrosis via a Galectin-3/mTOR Dependent Pathway
Abstract Number: 0973

Mechano-transduction via MRTF-A Pathway Is Required for Cytokine Release by Scleroderma Macrophages
Abstract Number: 0974

Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Abstract Number: 0976

Assessment of Current Trends in Demographic and Clinical Characteristics of Male Patients with Rheumatoid Arthritis in North India
Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Abstract Number: 0978

Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 0979

The Joint Project: A Community-Based, Barangay Health Worker-Led Screening Program for Childhood Musculoskeletal Disorders in a Barangay in San Pedro, Laguna, Philippines
Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort
Abstract Number: 0981

The Causal Effect of Sex Hormone-related Drugs on the Risk of Osteoarthritis – A Mendelian Randomization Study
Abstract Number: 0982

Urinary Incontinence Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 0983

Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Abstract Number: 0984

Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].